Learn if You Have a Claim Against Hoffman-La Roche, Inc. (maker of Accutane)

Acne Drug's Psychiatric Side-Effects Kahn Gauthier Swick is investigating possible legal actions against Hoffman-La Roche, Inc., manufacturer of the prescription acne drug Accutane, to recover for psychological damage--sometimes leading to suicide--suffered by Accutane users.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name
Age
Relationship
Accutane Acne Medication Use

Date you began taking Accutane
Date you stopped taking Accutane
Medical Information

Please describe the circumstances regarding the depression, suicide ideation or suicide.
Date of any violent act.
City in which any injury occured.
State in which any injury occured.
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

American Pharmaceuticals Partners Allegedly Overstated Potential of Breast Cancer Drug Abraxane

A class action has been filed against specialty pharmaceutical company American Pharmaceuticals Partners, Inc. (Nasdaq: APPX) and certain of its officers and directors by stockholders who purchased the company's common stock between February 19, 2002, and September 24, 2003.

Tripos Charged with Hiding Business Reverses

A class action has been filed against Tripos, Inc. (Nasdaq: TRPS) and certain of its officers and directors by stockholders who purchased the company's common stock between January 9 and July 1, 2002.

Walgreen Pharmacies’ One-Year Expiration Date Policy the Subject of Fraud Litigation

Prescription expiration dates should be obeyed to assure that your medication works effectively. A class action filed against Walgreen Company on behalf of prescription purchasers who claim that Walgreen’s policy of placing its own expiration dates of one year from the date of purchase on prescriptions dispensed wrongly denied them the full and safe use of the medications.

Odyssey Healthcare Shareholders Allege Hospice Programs Exceeded Medicare Reimbursements

Several class actions have been filed against hospice operator Odyssey Healthcare, Inc. (Nasdaq:ODSY) and certain of its officers and directors by stockholders who purchased the company's common stock between May 5, 2003, and February 23, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Bal Harbour, Florida, Residents of Harbour House South Apartments Reach Settlement Over Renovation Gone Wrong

Mold infestations can cause damage to your health and your property. The parties have reached a tentative settlement in a class action filed against Smith Property Holdings Harbour House South L.L.C. on behalf of residents who lived in Harbour House South, a 452-unit residential apartment building at 10275 Collins Avenue, Bal Harbour, Florida, and suffered due to a renovation of the building between November 1, 2000, and January 9, 2003. Claims must be on file by March 14, 2004, to be considered valid.

Merck Shareholders Cry Foul Over Handling of Vioxx Risks

Adding to the firestorm of litigation surrounding the recall of the pain drug Vioxx, several securities class actions have now been filed against pharmaceutical giant Merck & Co. (NYSE: MRK) and certain of its officers and directors by stockholders who purchased the company’s common stock between October 30, 2003 and September 30, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company’s securities. The stockholders seek to recover compensatory damages for the loss of value of their stock.